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Primary central nervous system lymphoma (PCNSL) is 
an uncommon form of extranodal non- Hodgkin’s lym-
phoma that arises within the central nervous system 
(CNS), most cases of which demonstrate diffuse large 
B- cell lymphoma (DLBCL) histology [1]. Although the 
etiology for the development of lymphoma in this extran-
odal site remains unclear, PCNSL patients are known 
to be characterized by high IL- 10/IL- 6 ratio in the cer-
ebrospinal fluid (CSF), and it may be speculated that 
PCNSL is derived from B cells with IL- 10- producing 
capacity.
In mouse models of multiple sclerosis (experimental 
autoimmune encephalomyelitis, EAE) and cerebral 
infarction, a population of IL- 10- producing B cells, 
named regulatory B cells, has been shown to have a 
function to migrate to the CNS and suppress inflam-
mation [2–4]. These regulatory B cells are reported to 
express a cell surface molecule T- cell immunoglobulin 
domain and mucin domain protein 1 (Tim- 1) at a 
high frequency [5].
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Abstract
Primary central nervous system lymphoma (PCNSL) is a distinct subtype of 
extranodal lymphoma with aggressive clinical course and poor outcome. As 
increased IL- 10/IL- 6 ratio is recognized in the cerebrospinal fluid (CSF) of 
PCNSL patients, we hypothesized that PCNSL might originate from a popula-
tion of B cells with high IL- 10- producing capacity, an equivalent of “regulatory 
B cells” in mice. We intended in this study to clarify whether Tim- 1, a molecule 
known as a marker for regulatory B cells in mice, is expressed in PCNSL. By 
immunohistochemical analysis, Tim- 1 was shown to be positive in as high as 
54.2% of PCNSL (26 of 58 samples), while it was positive in 19.1% of systemic 
diffuse large B- cell lymphoma (DLBCL) samples (17 of 89 samples; P < 0.001). 
Tim- 1 expression positively correlated with IL- 10 expression in PCNSL (Cramer’s 
V = 0.55, P < 0.001), and forced expression of Tim- 1 in a PCNSL cell line 
resulted in increased IL- 10 secretion, suggesting that Tim- 1 is functionally linked 
with IL- 10 production in PCNSL. Moreover, soluble Tim- 1 was detectable in 
the CSF of PCNSL patients, and was suggested to parallel disease activity. In 
summary, PCNSL is characterized by frequent Tim- 1 expression, and its soluble 
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Tim- 1 is a type I cell surface glycoprotein that is 
expressed on various immune cells, such as activated T 
cells, B cells, natural killer T (NKT) cells, and dendritic 
cells, and regulates diverse immune responses [6–12]. It 
is also known to be induced on tubular epithelial cells 
following kidney injury [13], and it is then cleaved at a 
membrane proximal point and the extracellular domain 
of the protein is released into the urine [14–16]. In B 
cells, Tim- 1 is shown to be expressed by a large majority 
of IL- 10- expressing population [5]. Regulatory B cells with 
defective Tim- 1 mutation have a profound defect in IL- 10 
production, suggesting that Tim- 1 plays a pivotal role in 
their IL- 10 production [17].
We hypothesized that PCNSL may originate from such 
B cells that have a physiological role in producing IL- 10 
to suppress unfavorable inflammation in the CNS. In this 
study, we found that Tim- 1 was detected in more than 
half of the PCNSL samples by immunohistochemistry, 
and Tim- 1 was also detectable in soluble form in the 
CSF of PCNSL patients with active disease. Our findings 
suggest that PCNSL is characterized by frequent Tim- 1 
expression, and detection of soluble Tim- 1 in CSF may 
be useful for the diagnosis and evaluating the disease 
activity of PCNSL.
Materials and Methods
Clinical samples, immunohistochemistry, 
and ELISA
For immunohistochemical analysis, formalin- fixed, 
paraffin- embedded samples of 48 PCNSL (median age 63; 
age range 16–86 years) and 89 systemic DLBCL patients 
(median age 67; age range 22–86 years) diagnosed at Kyoto 
University Hospital, Nagasaki University Hospital, Kobe 
Central Citizen Hospital, and Tenri Hospital were used. 
All PCNSL samples were obtained from immunocompetent 
patients at first diagnosis, and were of DLBCL histology. 
They were stained with anti- Tim- 1 antibody (MAB 1750; 
R&D Systems, Minneapolis, MN), anti- IL- 10 antibody 
(AF- 217; R&D Systems), anti- CD3 antibody (2GV6; 
Ventana Medical Systems, Tucson, AZ), and anti- CD20 
antibody (L26; DAKO, Carpinteria, CA). Cut- off values 
of Tim- 1 and IL- 10 positivity were set as 30%, according 
to the criteria that are commonly applied to the IHC 
analysis of lymphoma [18]. Statistical analysis was per-
formed using STATA 11 software (Stata Corporation, 
College Station, TX). The Chi- square test, Mann–Whitney 
U- test, t- test, and paired t- test were used for comparison 
between two groups. Fluorescent double staining was per-
formed by labeling anti- Tim- 1 antibody with FITC- 
conjugated donkey anti- mouse antibody (ab98770; Abcam, 
Cambridge, MA), and anti- IL- 10 antibody with rabbit 
anti- goat antibody (E0466; DAKO, Carpinteria, CA), and 
Alexa555- conjugated donkey anti- rabbit antibody 
(ab150070; Abcam). Nuclei were counterstained with DAPI 
(H- 1200; Vector Laboratories; Burlingame, CA).
CSF samples were collected from lymphoma patients 
after obtaining written informed consent, and were cen-
trifuged at 2000g for 10 min at 4°C and stored at −80°C 
until analysis. Soluble Tim- 1 levels of the CSF samples 
were analyzed by ELISA using Human Tim- 1/KIM- 1/
HAVCR Duoset (R&D Systems) following the manufac-
turer’s instructions. These clinical samples were obtained 
and used under the approval of the Institutional Review 
Board of each institute, and performed in accordance with 
the ethical standards of an institutional research commit-
tee and the provisions of the Declaration of Helsinki (as 
revised in 2013).
Gene expression analysis
The expression levels of TIM-1 and IL-10 genes were 
compared using the previously published datasets available 
in the NCBI GEO database (http://www.ncbi.nlm.nih.gov/
geo/). We picked up GEO series data and obtained the 
cell intensity files from the database. The CEL files were 
imported into the R software package (ver. 3.1.1., Free 
Software Foundation, Boston, MA), and the probe- level 
data were converted into normalized expression profiles 
using the Affy package [19]. The expression levels of each 
gene were normalized using ACTB.
Cell lines and immunoblot analysis
A PCNSL cell line, TK (JCRB1206), was obtained from 
JCRB Cell Bank (Tokyo, Japan). A Burkitt lymphoma cell 
line, Raji, a mantle cell lymphoma cell line, Granta 519, 
and a mouse fibroblast cell line, L cells, were as described 
elsewhere [20–22]. These cell lines were cultured in RPMI- 
1640 medium supplemented with 10% (or 20% for TK 
cells) heat- inactivated fetal calf serum (FCS), 100 μg/mL 
penicillin, 100 μg/mL streptomycin, and 2 mmol/L 
L- glutamine. A human embryonic kidney cell line, 293T, 
was cultured in DMEM containing 10% FCS, penicillin, 
streptomycin, and L- glutamine.
For immunoblot analysis, the cells were lysed in lysis 
buffer (25 mmol/L HEPES [pH 7.4], 150 mmol/L NaCl, 
1 mmol/L MgCl2, 1 mmol/L EDTA, 1.0% Triton X- 100, 
10% glycerol, and protease inhibitor cocktail). Total cell 
lysates and cell supernatants of the culture medium were 
subjected to sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis and transferred to Immobilon- P polyvi-
nylidene difluoride transfer membranes (Millipore, 
Bedford, MA). The membranes were immunoblotted with 
anti- Tim- 1 antibody (clone 219211; R&D Systems) or 
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anti- FLAG M2 monoclonal antibody (Sigma, St. Louis, 
MO). The membranes were subsequently incubated with 
horseradish peroxidase- conjugated anti- mouse secondary 
antibody, and immunoreactive proteins were visualized 
by enhanced chemiluminescence reaction using SuperSignal 
West Pico Chemiluminescent Substrate (Thermo Scientific, 
Rockford, IL).
TIM- 1 transfection assay
Human TIM-1 transcript was PCR amplified from cDNA 
of the lung adenocarcinoma cell line A549, which is known 
to express a high level of Tim- 1 [23], and subcloned into 
pFLAG- CMV- 5a expression vector (Sigma). The vector 
was transduced into 293T cells using X- tremeGENE HP 
DNA Transfection Reagent (Roche, Mannheim, Germany). 
Flag- tagged Tim- 1 was also subcloned into a pCS- CAG- 
EGFP lentiviral vector, which was constructed by replacing 
the CD19 promoter of Eμmar- L.CD19- EGFP vector with 
CAG promoter [24, 25]. The packaging plasmid pCAG- 
HIVgp and the VSV- G- and Rev- expressing plasmids 
(pCMV- VSV- G- RSV- Rev) were kindly provided by Dr. 
H. Miyoshi, RIKEN Bioresource Center, Tsukuba, Japan. 
TIM-1 expression vector was transfected into 293T cells 
with packaging plasmids, and viral supernatants were col-
lected after 48 h, concentrated by ultracentrifugation at 
20,000g for 2 h, and transduced in TK cells.
TIM-1 or mock- introduced 293T and TK cells were 
incubated for 12 h in a serum- free medium, and the cells 
and supernatants were separately collected and analyzed 
for Tim- 1 protein expression by immunoblotting. For cell 
viability assay, TK cells were resuspended in RPMI- 1640 
medium with 20% FCS at a concentration of 4 × 106/mL 
and seeded in a 96- well plate. After 24 and 48 h of culture, 
IL- 10 production from TK cells introduced with mock or 
TIM- 1 expression vectors was analyzed by ELISA, using 
Human IL- 10 Duoset (R&D Systems) following the manu-
facturer’s instructions. The cells were cultured with 15 μg/
mL cisplatin or 20 μmol/L dexamethasone for 12 and 24 h, 
and cell apoptosis was evaluated by propidium iodide (PI) 
staining (Biolegend, San Diego, CA) and FACS analysis.
T- cell proliferation and cytokine production 
analysis
TIM-1- expressing or mock vector was transfected into L 
cells, and supernatants were collected after culturing for 
12 h. Peripheral blood mononuclear cells of three healthy 
donors were first separated from peripheral blood on a 
Ficoll- paque density gradient (Sigma), and subsequently 
CD4+ and CD8+ T cells were collected using CD4 and 
CD8 MicroBeads and a magnetic- activated cell sorting 
(MACS) system (Miltenyi Biotec, Bergisch- Gladbach, 
Germany). CD4+ and CD8+ T cells were individually 
resuspended in the supernatants of L cells at a concentra-
tion of 1 × 106/mL, seeded in a 96- well plate, and cultured 
under stimulation with anti- CD3/CD28 beads (Life 
Technologies, Gaithersburg, MD). After 48 or 72 h of 
culture, cell numbers were counted and their supernatants 
were analyzed for cytokine production using the following 
ELISA kits: Human IL- 2 ELISA MAX Deluxe, Human 
IFN- gamma ELISA MAX Standard, Human IL- 17A ELISA 
MAX Deluxe Set (Biolegend, CA), Human IL- 4 ELISA 
Set (Becton Dickinson, Mountainview, CA), and Human 
IL- 10 Duoset (R&D Systems).
Results
Increased expression of Tim- 1 in PCNSL
We first performed immunohistochemical staining of Tim- 1 
and IL- 10 in 48 PCNSL and 89 systemic DLBCL samples 
(Fig. 1A, a). Tim- 1 and IL- 10 were positive in 17 (19.1%) 
and 14 (15.1%) of systemic DLBCL. In contrast, they 
were positive in 26 (54.2%) and 23 (47.9%) of PCNSL 
(vs systemic DLBCL, P < 0.001), and in most positive 
cases, both Tim- 1 and IL- 10 were stained in more than 
80% of the tumor cells. Steroids had been administered 
before biopsy in 10 PCNSL patients, but they did not 
seem to affect much on Tim- 1 expression (Cramer’s 
V = 0.15). Among systemic DLBCL, Tim- 1 was positive 
in 9 (26.5%) of 34 germinal center B- cell like (GCB) and 
in 8 of 55 non- GCB DLBCL evaluated by immunohisto-
chemistry based on Hans’ algorithm [18], suggesting that 
Tim- 1 expression was not significantly biased to either 
cell of origin (P = 0.178). Immunohistochemical staining 
of the serial sections and fluorescent double staining analysis 
indicated that Tim- 1 and IL- 10 were coexpressed in tumor 
B cells (Fig. 1A, b, c), and a moderate correlation was 
observed between their positivities (Cramer’s V = 0.55, 
P < 0.001) (Fig. 1B). In contrast, their correlation was 
lower in systemic DLBCL (Cramer’s V = 0.34, P < 0.005). 
There were five systemic DLBCL samples of the patients 
who subsequently developed CNS involvement, but all 
were negative for Tim- 1 while three were positive for 
IL- 10, and it was suggested that secondary CNS involve-
ment of systemic DLBCL is not associated with Tim- 1 
expression of the primary lesions.
We next compared the mRNA expression levels of 
TIM-1 and IL-10 in PCNSL and nodal DLBCL by using 
datasets from the GEO database (accession number: 
GSE10524 [26]). The expression of the TIM-1 gene 
was shown to be significantly higher in PCNSL than 
in nodal DLBCL (P < 0.001), and the expression of 
IL-10 also tended to be higher in PCNSL (Fig. 1C). 
Additionally, we collected two datasets (accession 
3238 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
W. Kishimoto et al.Expression of Tim- 1 in PCNSL
number: GSE4290 [27] and GSE34771 [28]) measured 
on the same GPL570 microarray platform, and after 
normalization using the RMA method, expression levels 
of TIM-1 and IL-10 were compared. We found that 
both genes were expressed significantly higher in PCNSL 
than in normal brain or other brain tumors (P < 0.001, 
Fig. 1D). These results suggest that Tim- 1 is expressed 
in PCNSL with high specificity at both mRNA and 
protein levels, and it tends to positively correlate with 
IL- 10 expression.
Figure 1. Increased expression of Tim- 1 in PCNSL. (A) (a) Representative immunohistochemical staining patterns of the (i) Tim- 1- positive and (ii) 
- negative samples, and (iii) IL- 10- positive and (iv) - negative samples (original magnification, ×600). (b) Representative results of the immunohistochemical 
staining of the serial sections of PCNSL samples (original magnification, ×100). (c) the fluorescent double staining for Tim- 1 and IL- 10 of PCNSL. (B) 
Pie charts showing IL- 10- positive rates in the Tim- 1- positive (left, n = 26) and - negative (right, n = 22) samples. (C) Comparison of the gene expression 
levels of TIM-1 and IL-10 between PCNSL (n = 9) and nodal DLBCL (n = 15) samples using microarray datasets available in the NCBI GEO database 
(accession number: GSE10524). (D) Comparison of the gene expression levels of TIM-1 and IL-10 between PCNSL (n = 34), normal brain (n = 23), 
astrocytoma (n = 26), glioblastoma (n = 81), and oligodendroglioma (n = 50) samples using microarray datasets available in the NCBI GEO database 
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Tim- 1 enhances IL- 10 expression in PCNSL
Next, we intended to clarify the biological relationship 
between Tim- 1 and IL- 10 expression. In a PCNSL- derived 
cell line, TK, endogenous Tim- 1 protein is expressed at 
a low level. We lentivirally introduced TIM-1-expressing 
or mock vector into TK cells, and compared their IL- 10 
production by ELISA. Notably, the enhanced expression 
of Tim- 1 resulted in increased IL- 10 production in TK 
cells but not in other B- cell lymphoma lines, Raji and 
Granta 519 (Fig. 2A), suggesting that Tim- 1 augments 
IL- 10 expression in a PCNSL- specific cell condition.
To examine whether Tim- 1 has any role in the survival 
of PCNSL cells, we cultured TIM-1 and mock- introduced 
TK cells with cisplatin or dexamethasone. Although the 
































































































































































Cramer’s V = 0.55 (   <.001)
Figure 1. (Continued)
3240 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
W. Kishimoto et al.Expression of Tim- 1 in PCNSL
susceptibility to dexamethasone, it decreased the rate of 
cell death caused by cisplatin (Fig. 2B), suggesting that 
Tim- 1 may also confer chemoresistance on PCNSL cells.
Soluble Tim- 1 in the CSF of PCNSL patients
As Tim- 1 is expressed in tubular epithelial cells following 
kidney injury [13] and its soluble form is reported to be 
released into the urine [14–16], we examined whether 
the soluble form of Tim- 1 is also released from PCNSL 
cells. We transfected TIM-1 expression vector into 293T 
and TK cells, and their supernatants were examined for 
Tim- 1 protein by immunoblotting (Fig. 3A). Tim- 1 was 
detected in each supernatant by anti- Tim- 1 antibody, which 
reacts with the extracellular domain of the protein, and 
it was slightly smaller in size than those observed in the 
cell lysate. On the other hand, Tim- 1 protein was not 
detected in the supernatant when anti- FLAG antibody was 
used, which reacts with the FLAG epitope on the 
C- terminus, suggesting that the soluble form of this protein 
lacks the C- terminus. Instead, a small remnant protein 
was detected in the cell lysate by this antibody. These 
results suggest that, as is reported in tubular epithelial 
cells, Tim- 1 is cleaved near the C- terminus and its extra-
cellular domain is released from these cells.
These results led us to examine whether the soluble 
form of Tim- 1 is also released from PCNSL cells in 
vivo, and we examined Tim- 1 protein in the CSF of 
lymphoma patients by ELISA (Fig. 3B). Among 12 CSF 
samples obtained from PCNSL patients before treatment, 
Tim- 1 was detected in eight, and the rest four samples 
were of patients who had been administered systemic 
steroids before sampling. On the other hand, Tim- 1 was 
not detected in the CSF of a T- cell lymphoma patient 
with secondary CNS involvement, or systemic DLBCL 
patients without CNS involvement. Soluble Tim- 1 became 
undetectable in the patients who had achieved complete 
remission, but it remained positive in the patients with 
refractory disease (Fig. 3C). In PCNSL patient #2, radio-
logical examination of the tumor suggested a good 
response to chemotherapy, although Tim- 1 level in the 
CSF remained high. After 2 months, the patient relapsed 
with numerous small brain lesions and CSF dissemina-
tion. These results suggest that soluble Tim- 1 in the 
CSF can also reflect the presence of radiologically unde-
tectable tumor cells, and it is expected to serve as a 
useful biomarker for PCNSL.
Role of Tim- 1 in the tumor microenvironment
To clarify whether soluble Tim- 1 has any role in the 
tumor microenvironment, we examined its effect on T- cell 
function. We collected peripheral CD4+ and CD8+ T cells 
from healthy donors, and stimulated them with anti- CD3/
CD28 beads in vitro in the presence or absence of soluble 
Tim- 1 produced by L cells (Fig. 4A). We found that the 
proliferation of CD4+ T cells was suppressed by soluble 
Tim- 1 (P < 0.01), and proliferation of CD8+ T cells also 
tended to be inhibited (Fig. 4B). Additionally, IL- 2 and 
IFN- γ production of CD4+ T cells after 48 h of culture 
was suppressed in the presence of soluble Tim- 1, whereas 
the production of other cytokines was less affected 
(Fig. 4C). According to these results, it is suggested that 
the soluble form of Tim- 1 released from PCNSL cells has 
Figure 2. The functional role of Tim- 1 played in PCNSL cells. (A) 
Comparison of fold changes in IL- 10 production of Raji, Granta519, and 
TK cells introduced with TIM-1- expressing and mock vectors. (B) Cell 
death rates of TK cells introduced with TIM-1-expressing or mock 
vectors, which were evaluated by propidium iodide (PI) staining after 
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some immunomodulatory functions, and it may have a 
potential role in creating a microenvironment favorable 
for tumor cells.
Discussion
In this study, we have reported that Tim- 1, a molecule 
known as a specific marker for regulatory B cells in mice, 
is characteristically expressed in PCNSL. About 90–95% 
of PCNSLs demonstrate DLBCL histology, whereas they 
exhibit some distinct clinical features from systemic DLBCL, 
such as site- confined progression and high responsiveness 
to methotrexate therapy [29]. Histological and molecular 
studies of PCNSL to date have revealed the frequent 
expression of MUM- 1 and Bcl- 6 [30–32], high 
proliferative activity [33], recurrent BCL6 translocation, 
and deletion of 6p21.3 [34]. NF- κB pathway is generally 
activated in PCNSL, and gene alterations that lead to its 
deregulation, such as activating mutations of CARD11 and 
MYD88, are often involved [35–38].
Four functional TIM genes in mice and three in humans 
(TIM-1, TIM-3, and TIM-4) have been identified to date, 
and these TIM family members have multiple roles in 
regulating immune response. Tim- 1 functions as a costimu-
latory molecule following T- cell receptor (TCR) signaling, 
particularly after Th2 polarization [7–9]. Additionally, 
Tim- 1 has been reported to be a major ligand for endothe-
lial P- selectin, and have a function to regulate T- cell 
trafficking in inflamed tissues [39, 40]. Tim- 1 is also 
expressed in other immune cells such as dendritic cells 
Figure 3. Shedding of Tim- 1 ectodomain and detection of soluble Tim- 1 in the cerebrospinal fluid (CSF) of PCNSL patients. (A) Immunoblot analysis 
of 293T and TK cells transfected with TIM-1 expression vector. The cells and supernatants were separately analyzed for Tim- 1 protein using anti- Tim- 1 
and anti- FLAG antibodies, which recognize the extracellular domain and FLAG on the C- terminus, respectively. Arrowheads indicate different forms 
of Tim- 1 protein: full- length form (cell lysate), soluble form without C- terminus (supernatant), and remnant protein (cell lysate). (B) Soluble Tim- 1 
levels in the CSF of lymphoma patients analyzed by ELISA. (C) Clinical course of the two representative PCNSL patients. PCNSL #1: Tim- 1 in CSF 
became undetectable after successful treatment of whole- brain irradiation. PCNSL #2: Tim- 1 level remained high after chemotherapy while radiological 
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Figure 4. Immunomodulatory effect of soluble Tim- 1. (A) Schematic diagram of the experiment. CD4+ and CD8+ T cells of the healthy donors were 
stimulated with anti- CD3/CD28 beads with or without soluble Tim- 1 produced by L cells, and analyzed for cell proliferation and cytokine production. 
Soluble form of Tim- 1 was detected in the supernatant of L cells transfected with TIM-1 expression vector but not with mock vector (data not shown). 
(B) Effect of soluble Tim- 1 on T- cell number. (C) Effect of soluble Tim- 1 on cytokine production of CD4+ and CD8+ T cells.
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and mast cells, and plays different roles in each cell type 
[41–44].
As for B cells, Tim- 1 was reported to be expressed 
on a population that has immunosuppressive function, 
called regulatory B cells, in mice [5]. Tim- 1- positive B 
cells were shown to be highly enriched for IL- 10 and 
IL- 4 expression, promote Th2 responses, and be able to 
transfer allograft tolerance directly. These immunosup-
pressive B cells have been indicated to participate in the 
alleviation of brain inflammation in mouse models of 
multiple sclerosis (EAE) and cerebral infarction [2–4]. 
Little information is available on the function of B cells 
in the human brain, but there is a report of nonvasculitic 
autoimmune meningoencephalitis that developed after 
rituximab therapy against rheumatoid arthritis [45]. Brain 
biopsy showed a lack of B cells in the brain tissue, and 
the authors hypothesize that the depletion of regulatory 
B cells potentially triggered the autoimmune reaction in 
the brain.
We found high expression of Tim- 1 in PCNSL by 
histological analysis of the clinical samples. Gene expres-
sion analysis using the GEO database also found high 
Tim- 1 expression in PCNSL compared to other brain 
tumors, although we were not able to compare with 
inflammatory brain disorders. Tim- 1 tended to be 
expressed concurrently with IL- 10, and it was suggested 
to enhance IL- 10 production in PCNSL cells. Such asso-
ciation between Tim- 1 and IL- 10 was not observed in 
other B- cell lines, and is considered to be specific to 
PCNSL cells. Mouse regulatory B cells with defective 
Tim- 1 were reported to exhibit low IL- 10 expression [17], 
suggesting that Tim- 1 is necessary for IL- 10 production 
in regulatory B cells. The relationship between Tim- 1 
and IL- 10 in PCNSL suggests biological similarity of 
PCNSL to regulatory B cells.
We also found that the extracellular domain of Tim- 1 
is released from PCNSL cells, and soluble Tim- 1 is detected 
in the CSF of PCNSL according to disease activity. An 
increased IL- 10/IL- 6 ratio in the CSF is known to be 
useful for the diagnosis of PCNSL, but it is often difficult 
to measure accurately in clinical practice because of its 
instability. The half- life of Tim- 1 is longer than that of 
IL- 10 (about 6 h vs 1–2.6 h) [46–48], and it can be a 
more clinically applicable biomarker, although further 
examination is required. In contrast, serum Tim- 1 levels 
varied among healthy controls irrespective of renal func-
tion in our preliminary analysis, and it did not seem to 
be useful as a biomarker.
In summary, we found that Tim- 1 is characteristically 
expressed in PCNSL. In addition to its potential useful-
ness as a clinical biomarker, Tim- 1 is expected to be a 
key molecule for the better understanding and improved 
clinical management of PCNSL.
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